Document is current
Any future updates will be listed below
-
Authors
Berry, Catherine http://orcid.org/0000-0001-6363-9387
du Cros, Philipp
Fielding, Katherine
Gajewski, Suzanne
Kazounis, Emil
McHugh, Timothy D.
Merle, Corinne
Motta, Ilaria
Moore, David A. J.
Nyang’wa, Bern-Thomas
- License Information
-
More Information
Article History
Received: 25 November 2021
Accepted: 23 April 2022
First Online: 13 June 2022
Declarations
:
: The study protocol, the participant Information and Consent Form (ICF), the eCRF, up-to-date versions of the Investigator Brochures or Summary of Product Characteristics (SmPC), as well as Principal Investigators qualifications has been submitted and approved by the following ethical boards:UnorderedList removedThe study did not start in any centre before written approval by these Ethics Committees had been obtained, the local regulatory requirements had been complied with, and the signature of the clinical study protocol of each contractual party involved had been obtained.Written, informed consent to participate will be obtained from all participants.
: See annex.
: Philipp du Cros has received funding from TB Alliance for a project to analyse introduction and scale up of pretomanid and the NIX-TB regimen. Philipp du Cros is a member of the rGLC WPRO region. CM is currently staff members of the World Health Organization; the authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy or views of the WHONo other authors had conflicts to declare.
